Study of BMN-270 at a dose of 4e13vg/kg in patients with severe haemophilia A

Trial Profile

Study of BMN-270 at a dose of 4e13vg/kg in patients with severe haemophilia A

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs BMN 270 (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 Results published in the BioMarin Pharmaceutical media release.
    • 02 Aug 2017 According to a BioMarin Pharmaceutical media release, the study will include fewer than 100 patients.
    • 11 Jul 2017 According to BioMarin Pharmaceutical media release, the company intends to initiate this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top